The United States Senate Special Committee on Aging recently hosted a meeting entitled “The Fight Against Alzheimer’s Disease: Are We on Track to a Treatment by 2025?” The meeting featured the personal testimonies of Dr.Ronald Petersen from the Mayo Clinic, a top Alzheimer’s researcher and former member of the national Alzheimer’s Association; B. Smith,…
Currently incurable, Alzheimer’s disease (AD) is projected by the Centers for Disease Control to afflict some 13.8 million people in the U.S. by 2050 if effective new treatments are not discovered. Already, millions of U.S. residents are living with severe, disabling, and progressively degenerative Alzheimer’s-related dementia. Dr. Thomas…
Amarantus BioSciences Holdings, Inc., a biotechnology firm advancing diagnostic and therapeutic products for orphan diseases in the areas of neurology, ophthalmology, psychiatry and regenerative medicine, recently announced that Mr. Gerald E. Commissiong, CEO and President, will be presenting at the Neurotech Investing and Partnering Conference being held at the Hotel Nikko…
Thanks to its successful drugs to address treatments for multiple sclerosis, Biogen Idec Inc has seen its position in the biopharmaceutical market increase, having quadrupled sales in just 3 years to over $100 billion dollars. The company now has new ambitions in sight and has dropped “Idec” from its name and adopted…
Researchers at the Mayo Clinic and Foundation in Minnesota revealed that within the natural aging process, men have worse memory performance than women. The study was recently published in the journal JAMA Neurology and is entitled “Age, Sex, and APOE ε4 Effects…
Researchers at the UCSDÂ and Creighton University at Omaha, Nebraska say the National Academy of Sciences (NAS) Institute of Medicine (IOM)’s Recommended Dietary Allowance (RDA) for vitamin D intake is miscalculated and underestimated — not by any small measure, but by a whopping factor of ten.
Biogen Idec recently announced the results from a pre-specified interim analysis of PRIME, an ongoing Phase 1b randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of aducanumab (BIIB037) in patients with early or mild Alzheimer’s disease. The results were presented at the 12th International Conference…
The Innovative Medicines Initiative (IMI) together with the Global Alzheimer’s Platform (GAP) recently announced the signing of a Memorandum of Understanding (MOU) agreement based on the common goal of accelerating the search for an Alzheimer’s disease therapy through the creation of a global, standing, trial-ready platform for…
Researchers at the Rush University Medical Center, Chicago, IL and Harvard School of Public Health in Boston recently published results from an observational study that showed when a patient’s dietary intake is modified it could significantly lower their risk of developing Alzheimer’s disease (AD). The study entitled, “…
Results from the first ever randomized controlled trial of its kind shows that providing older people at risk of dementia with healthy eating assistance, brain training, exercise, and management of metabolic and vascular risk factors slows down cognitive decline. The study, entitled the Finnish Geriatric Intervention Study…
Get regular updates to your inbox.